21st Century Cures: Data Reliance Provision May Raise Exclusivity Issues
This article was originally published in The Pink Sheet Daily
FDA can use previously generated data when reviewing rare disease drugs targeted at small subsets.
You may also be interested in...
Congressional ‘Cures’ Debate Shifts To FDA Funding
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
FDA Orphan Approval Flexibility Remains Steady As Pressure Increases
Frank Sasinowski updates his 2012 landmark analysis and finds that FDA maintained its rate of flexibility in the evidentiary standards for approval of orphan products.
More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.